IRC-Galleria

Disease models used for gastroenterology research are essential tools for understanding the pathophysiology of GI disorders, testing potential therapies, and driving forward clinical applications. Common models include in vitro models (cell culture models, organoids) and animal models (rat, mouse, non-human primates, etc.). In vitro models are used for studying cellular and molecular mechanisms of GI diseases like IBD, colorectal cancer, and infectious enteropathies. Animal models can provide insights into disease mechanisms and preclinical drug testing.

As a leading gastroenterology CRO, Ace Therapeutics provides tailored preclinical gastrointestinal disease models using CRISPR genome editing, microbiome engineering, and rodent surgery for fast-track disease discovery and drug discovery. To be more specific, Ace Therapeutics' disease models mimic human GI pathophysiology with unprecedented accuracy, incorporating organoids and multi-omics data integration. This enables researchers to study disease progression and therapeutic responses in a controlled, scalable environment.

In addition, Ace Therapeutics' disease models are suitable for comprehensive coverage of GI disorders. From ulcerative colitis and Crohn's disease to non-alcoholic steatohepatitis (NASH) and gastric cancer, Ace Therapeutics offers an extensive portfolio. Each model incorporates key pathological features, such as immune dysregulation, microbiome interactions, and tissue fibrosis, enabling multi-target drug testing.

Leveraging advanced gene-editing, organoid cultures, and AI-driven data analytics, the models from Ace Therapeutics allow for personalized research approaches. Whether investigating novel biologics, small molecules, or microbiome-based therapies, researchers can tailor studies to specific mechanisms of interest. Furthermore, by minimizing variability and enhancing reliability, Ace Therapeutics can help shorten preclinical timelines and reduce R&D costs. Pharmaceutical companies and academic labs alike can expedite breakthroughs while optimizing resource allocation.

With a proven track record in gastroenterology research, Ace Therapeutics is the preferred gastroenterology CRO for biopharma innovators. Whether researchers are developing anti-fibrotic therapies, metabolic modulators, or oncology drugs, Ace Therapeutics' gastrointestinal and liver disease models deliver the robust preclinical data they need. Learn more, please see biliary disease models.

About Ace Therapeutics
Ace Therapeutics is a preclinical contract research organization dedicated to advancing research in gastroenterology and hepatology. With decades of experience developing preclinical research platforms, Ace Therapeutics supports customers in gaining insights into disease mechanisms and translating those findings into novel solutions.

As a preclinical contract research provider dedicated to offering comprehensive research services, Ace Therapeutics provides a complete one-stop service for developing custom animal models to support preclinical psychiatry research. The opportunity to apply such models towards revolutionizing research in mental health can allow for the discovery of novel therapies for these disorders.

“Psychiatry research faces a number of hurdles to the translation of preclinical discoveries into effective treatments,” said the senior chief scientist at Ace Therapeutics. “We pride ourselves on being able to create customized animal models, enabling researchers to make more sense of the complexities surrounding mental health disorders and developing efficient therapeutic adjuncts.”

Current challenges in preclinical psychiatry research
At this stage, preclinical research on mental diseases has many challenges and difficulties, such as animal models are limited, pathological mechanisms are complex, drug targets are unclear, and behavioral testing methods are not advanced enough. To this end, preclinical studies on psychiatric disorders may have to create more productive animal and in vitro models and enhance biomarker discovery and validation to accelerate the discovery of novel therapeutic strategies for psychiatric diseases.

Through approaches such as selective breeding, genetic engineering, brain injury, and environmental manipulation, Ace Therapeutics has developed a range of animal models for psychiatric research. These models represent attempts to simulate, as much as possible, the neurobiological or behavioral pathology of human diseases. Therefore, it can help researchers elucidate disease pathophysiology and also expedite therapeutic development targeting novel molecular targets.

Some of the main features of Ace Therapeutics’ animal models include:
– Genetically-Engineered Models: Models that can be genetically engineered to manifest specific traits related to different psychiatric conditions such as depression, anxiety, and autism, enabling targeted research.

- Robust Validation: Extensive validation studies are performed with experienced psychiatric researchers to confirm that the models accurately represent human pathophysiology.

In this context, the launch of Ace Therapeutics’ preclinical psychiatry models comes in response to increasing demand for better preclinical research tools. Utilizing leading-edge genetic modification and behavioral evaluation techniques, Ace Therapeutics offers researchers the ability to model a multitude of psychiatric disorders with unparalleled precision. The company is confident that these models can facilitate groundbreaking discoveries and accelerate the pathway from bench to bedside. Learn more about Ace Therapeutics’ microelectrode array.

About Ace Therapeutics
With a team of experienced researchers and state-of-the-art facilities, Ace Therapeutics strives to accelerate the development of innovative mental illness therapies. From basic research services to therapeutic development services, Ace Therapeutics offers tailored solutions to facilitate psychiatric drug development, enabling the transformation of promising concepts into promising therapeutic candidates.

Animal models have been fundamental to the advancement of knowledge regarding inflammatory bowel disease, such as Crohn's disease and ulcerative colitis. Animal models allow scientists to investigate disease mechanisms, evaluate drug candidates, and analyze the complex interaction among genetics, immune system, and gut microbiota. Being a leading preclinical CRO for IBD, Ace Therapeutics offers a comprehensive range of customized in vivo and in vitro models of IBD to support drug discovery and preclinical development programs.

Ace Therapeutics’ IBD Model Portfolio
 Chemical-induced models
 T cell transfer models
 Anti-CD40-induced colitis models
 Spontaneous gene mutation models
 Genetically engineered models
 Bacterial-induced models

With these models, Ace Therapeutics can help researchers analyze several readouts, including immunofluorescence (IF), immunohistochemistry (IHC), ELISA, in situ hybridisation (RNAscope), and cytokine profiling.

Key Features of Ace Therapeutics’ IBD Models
 Precision-Driven Design
The models incorporate genetic, immunological, and microbiome variables to mimic human IBD subtypes (e.g., Crohn’s disease, ulcerative colitis), enabling researchers to study disease mechanisms and therapeutic responses with unprecedented accuracy.
 Regulatory-Ready Framework
Developed in compliance with stringent medical device and pharmacovigilance standards, these models align with global regulatory expectations, including the In Vitro Diagnostic Regulation (IVDR).
 Integration with AI-Powered Analytics

Researchers can leverage Ace Therapeutics’ proprietary platform to analyze drug efficacy, adverse events, and biomarker correlations, streamlining data interpretation for faster decision-making.

Ace Therapeutics’ experimental models mimic aspects of IBD in humans and can be used to generate target validation and mechanism of action data to confirm the efficacy of novel therapies. Tailored models allow testing of condition-specific therapies, advancing the shift toward precision treatment. In addition to disease models, Ace Therapeutics also provides IBD drug development services, IBD pathogenesis analysis, and IBD biomarker discovery.

Drug metabolism and pharmacokinetics (DMPK) play a crucial role in the drug development process for stroke. DMPK studies involve the evaluation of how drugs are metabolized and distributed in the body, as well as how they are eliminated from the body. These studies provide important information about the safety and efficacy of a drug and help researchers determine the optimal dosing regimen for a particular drug.

Ace Therapeutics is an innovative stroke CRO company focusing on early drug discovery services from behavioral assessment of cognition and in vitro ischemic stroke models to preclinical candidate identification and efficacy evaluation, with strong capabilities and technologies in the stroke field. Based on a broad portfolio of services and a global network of partners, Ace Therapeutics can analyze NR2A-CREB-BDNF signaling pathway in stroke.

The ADME/DMPK services at Ace Therapeutics include a comprehensive suite of in vitro and in vivo ADME studies to assess the absorption, distribution, metabolism, and excretion of drug candidates, as well as their pharmacokinetic properties. In addition, comprehensive analysis of PK/TK, trans-BBB PK, and PK/PD in stroke drug development are also included in the ADME/DMPK services. According to clients’ needs, these services can be offered in a customized module. By providing valuable insights into the behavior of drug compounds in the body, these services will enable researchers to make informed decisions throughout the drug development process.

“We are proud to offer our ADME/DMPK services to enhance the stroke drug development process,” said the marketing manager of Ace Therapeutics. “Our state-of-the-art facilities and experienced scientists will work closely with our partners to optimize drug candidates for efficacy and safety, ultimately leading to the advancement of new treatments for stroke patients.”

With the introduction of the ADME/DMPK services, Ace Therapeutics is now equipped to help pharmaceutical companies and research institutions accelerate the discovery and development of novel stroke therapies. For more information about Ace Therapeutics' ADME/DMPK services for stroke drug development, please visit www.acetherapeutics.com/stroke/.